Intellia Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTLA

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. 

CEO
John M. Leonard
CEOJohn M. Leonard
Employees
377
Employees377
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
377
Employees377

NTLA Key Statistics

Market cap
1.57B
Market cap1.57B
Price-Earnings ratio
-3.25
Price-Earnings ratio-3.25
Dividend yield
Dividend yield
Average volume
5.08M
Average volume5.08M
High today
$11.53
High today$11.53
Low today
$11.08
Low today$11.08
Open price
$11.26
Open price$11.26
Volume
2.38M
Volume2.38M
52 Week high
$28.25
52 Week high$28.25
52 Week low
$7.95
52 Week low$7.95

Stock Snapshot

Intellia Therapeutics(NTLA) stock is priced at $11.30, giving the company a market capitalization of 1.57B. It carries a P/E multiple of -3.25.

On 2026-07-22, Intellia Therapeutics(NTLA) stock traded between a low of $11.08 and a high of $11.53. Shares are currently priced at $11.30, which is +2.0% above the low and -2.0% below the high.

Intellia Therapeutics(NTLA) shares are trading with a volume of 2.38M, against a daily average of 5.08M.

During the past year, Intellia Therapeutics(NTLA) stock moved between $7.95 at its lowest and $28.25 at its peak.

During the past year, Intellia Therapeutics(NTLA) stock moved between $7.95 at its lowest and $28.25 at its peak.

NTLA News

Simply Wall St 1d
Intellia Therapeutics Stock And 2 High Growth Shares With Strong Balance Sheets

With inflation, energy costs and interest rates all under close watch, many investors are looking for companies that pair solid balance sheets with the prospect...

Intellia Therapeutics Stock And 2 High Growth Shares With Strong Balance Sheets
Simply Wall St 6d
Intellia Therapeutics Resumes Key Trials, Is The Undervalued Case Still Convincing?

The FDA’s decision to lift clinical holds on Intellia Therapeutics (NTLA)’s MAGNITUDE and MAGNITUDE-2 trials has refocused attention on the stock, as patient en...

Intellia Therapeutics Resumes Key Trials, Is The Undervalued Case Still Convincing?

Analyst ratings

50%

of 20 ratings
Buy
50%
Hold
35%
Sell
15%

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.